Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | FPR3 | P25089 | 4/20 | 0.44 |
| ▸ | FPR2 | P25090 | 4/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | POLR1A | O95602 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13831072 | 0.92 | KMT2A (0.55) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL17428292 | 0.90 | KMT2A (0.57) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL11973925 | 0.88 | KMT2A (0.55) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL12009838 | 0.88 | KMT2A (0.58) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL17428294 | 0.88 | KMT2A (0.54) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL9167791 | 0.87 | KMT2A (0.60) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL14749803 | 0.87 | KMT2A (0.53) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL5654310 | 0.86 | KMT2A (0.62) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL4548019 | 0.84 | KMT2A (0.61) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL20016690 | 0.84 | KMT2A (0.57) | KMT2ARAB9AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009656-A1 | SUPRAMOLECULAR MATERIALS MADE OF OLIGOAMIDES | ARKEMA FRANCE (FR) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009656-A1 | SUPRAMOLECULAR MATERIALS MADE OF OLIGOAMIDES | ORC3, PCNA, PARN | KMT2A 2029/4885RAB9A 4761/4885KDM4E 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.